抗抑郁药物的现状与新靶点的探索

The Current Status of Antidepressant Drugs and the Exploration of New Targets

摘要: 抑郁症是一种常见的病因复杂、影响着全球数百万人的精神障碍，药物治疗是主要的治疗方式。但当前的抗抑郁药多基于“单胺神经递质假说”开发，如SSRI和SNRI。这些药物通过调节5-HT和NE的浓度来缓解抑郁症状。然而，这些药物起效慢(通常需2~3周)且存在胃肠道不适、性功能障碍等副作用，长期用药后存在复发风险等。此外，约20%~30%的患者对这些药物无显著反应。为了解决现有治疗药物的局限性，近年来开发了多种基于新型的抗抑郁靶点的药物，如谷氨酸系统中的NMDA受体拮抗剂氯胺酮，已被证明对难治性抑郁症有快速起效的效果。同时，针对其他新型靶点如AMPA受体、mGluR受体、神经肽系统、离子通道和炎症标志物等的新药也显示出良好的治疗前景。这些新型药物不仅能改善情绪，还可能提高认知功能和神经可塑性。本文对这些研究进展进行了简要但系统的综述。

Abstract: Depression, a prevalent mental disorder with multifaceted origins, impacts millions globally. Pharmacological interventions form the primary treatment approach. However, most current antidepressants are grounded in the “monoamine neurotransmitter hypothesis,” including SSRIs and SNRIs, which alleviate depressive symptoms by modulating 5-HT and NE levels. Despite their efficacy, these medications exhibit a delayed onset of action (usually 2~3 weeks) and can cause side effects like gastrointestinal issues and sexual dysfunction. Moreover, there is a risk of relapse following prolonged use, and about 20%~30% of patients do not respond significantly to these treatments. To address these limitations, recent years have seen the development of novel antidepressants targeting different mechanisms. For example, ketamine, an NMDA receptor antagonist within the glutamate system, has shown rapid efficacy in treating resistant depression. Concurrently, emerging drugs that target other innovative pathways, such as AMPA receptors, mGluR receptors, neuropeptide systems, ion channel and inflammatory markers, also hold promising therapeutic potential. These new agents not only enhance mood but may also improve cognitive function and neuroplasticity. This paper offers a concise yet comprehensive overview of these advancements in research.